ADMA Biologics Inc (NASDAQ:ADMA) Expected to Announce Earnings of -$0.26 Per Share

Analysts predict that ADMA Biologics Inc (NASDAQ:ADMA) will post ($0.26) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for ADMA Biologics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.13). ADMA Biologics posted earnings per share of ($0.35) in the same quarter last year, which would indicate a positive year over year growth rate of 25.7%. The company is scheduled to issue its next quarterly earnings results on Friday, August 9th.

According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.34) to ($0.79). For the next fiscal year, analysts forecast that the business will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.94) to ($0.03). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01. The business had revenue of $3.53 million during the quarter, compared to analyst estimates of $2.96 million. ADMA Biologics had a negative return on equity of 210.69% and a negative net margin of 370.27%.

Several research firms have recently issued reports on ADMA. HC Wainwright set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Thursday, May 23rd. Oppenheimer set a $14.00 price objective on ADMA Biologics and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, Jefferies Financial Group began coverage on ADMA Biologics in a research note on Tuesday, June 4th. They issued a “buy” rating and a $8.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $11.40.

Shares of NASDAQ:ADMA traded down $0.07 during trading on Friday, hitting $3.48. The company had a trading volume of 447,937 shares, compared to its average volume of 554,047. The company has a market cap of $200.45 million, a PE ratio of -2.40 and a beta of 2.71. ADMA Biologics has a one year low of $2.08 and a one year high of $6.96. The stock has a fifty day moving average price of $3.77. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60.

In other ADMA Biologics news, insider Adam S. Grossman purchased 30,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was purchased at an average cost of $4.00 per share, with a total value of $120,000.00. Following the purchase, the insider now owns 37,527 shares of the company’s stock, valued at $150,108. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 4,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were acquired at an average cost of $4.00 per share, with a total value of $16,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,064,500 shares of company stock valued at $16,258,000 over the last three months. 15.20% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of ADMA. United Services Automobile Association bought a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $27,000. Dimensional Fund Advisors LP bought a new stake in ADMA Biologics during the 4th quarter valued at $34,000. Raymond James & Associates raised its position in ADMA Biologics by 65.2% during the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares in the last quarter. Geode Capital Management LLC raised its position in ADMA Biologics by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares in the last quarter. Finally, BlackRock Inc. raised its position in ADMA Biologics by 0.5% during the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock valued at $2,305,000 after purchasing an additional 4,577 shares in the last quarter. 38.70% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: Portfolio Manager

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.